Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine by Adelaide H. McClintock et al.
RESEARCH ARTICLE Open Access
Treatment completion for latent
tuberculosis infection: a retrospective
cohort study comparing 9 months of
isoniazid, 4 months of rifampin and
3 months of isoniazid and rifapentine
Adelaide H. McClintock1*†, McKenna Eastment2†, Christy M. McKinney1, Caroline L. Pitney3, Masahiro Narita4,5,
David R. Park4ˆ, Shireesha Dhanireddy2 and Alexandra Molnar1
Abstract
Background: The U.S. Centers for Disease Control and Prevention (CDC) recommended a new regimen for treatment
of latent tuberculosis (three months of weekly isoniazid and rifapentine) in late 2011. While completion rates of this
regimen were reported to be higher than nine months of isoniazid, little is known about the completion rates of three
months of isoniazid and rifapentine compared to nine months of isoniazid or four months of rifampin in actual use
scenarios.
Methods: We conducted a retrospective cohort study comparing treatment completion for latent tuberculosis (TB)
infection in patients treated with nine months of isoniazid, three months of isoniazid and rifapentine or four months of
rifampin in outpatient clinics and a public health TB clinic in Seattle, Washington. The primary outcome of treatment
completion was defined as 270 doses of isoniazid within 12 months, 120 doses of rifampin within six months and 12
doses of isoniazid and rifapentine within four months.
Results: Three hundred ninety-three patients were included in the study. Patients were equally likely to complete
three months of weekly isoniazid and rifapentine or four months of rifampin (85% completion rate of both regimens),
as compared to 52% in the nine months of isoniazid group (p < 0.001). These associations remained statistically
significant even after adjusting for clinic location and type of monitoring. Monitoring type (weekly versus monthly
versus less often than monthly) had less impact on treatment completion than the type of treatment offered.
Conclusions: Patients were equally as likely to complete the three months of isoniazid and rifapentine as four months
of rifampin. Four months of rifampin is similar in efficacy compared to placebo as isoniazid and rifapentine but does not
require directly observed therapy (DOT), and is less expensive compared to combination therapy with isoniazid and
rifapentine, and thus can be the optimal treatment regimen to achieve the maximal efficacy in a community setting.
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Background
Treating latent TB infection (LTBI) in high-risk individ-
uals is one of the eight Millennium Development goals
of the United Nations [1]. In the United States alone,
9,421 cases of active TB were reported in 2014 [2], and
it is estimated that more than 13 million people have la-
tent TB infection [3, 4]. Aggressive treatment of LTBI
provides significant cost-savings and quality-adjusted life
years saved because it dramatically reduces the risk of
progression to active TB [5]. Most of the cases in the
United States occur in foreign born individuals [6]. In
fact, TB in foreign born individuals is on the rise in the
US [6]. Primary care and Public Health clinics are often
the first contact newly arrived patients have with the
health care system for screening for TB infection.
With the availability of novel treatment regimens for
LTBI, medical providers now face the challenge of
choosing which regimen is best suited for an individual
patient. Historically, the regimen of choice for LTBI was
nine-months of daily isoniazid [7]. Nine months of iso-
niazid reduces the rate of progression to active TB by up
to 39-86%, but only if the patient is fully adherent [7, 8].
In most actual use studies, isoniazid completion rates
are only 31-59% [9–11] making it a less effective treat-
ment choice in non-research settings [7]. Additionally,
use is limited by the concerns for side effects such as
hepatotoxicity and neuropathy [7].
In 2011, the CDC recommended a three-month directly
observed, weekly dosed therapy of isoniazid and rifapen-
tine as an “equal alternative” to the nine month isoniazid
regimen [12] in healthy individuals with LTBI. Based on
three randomized controlled trials [13–15], isoniazid and
rifapentine with directly observed therapy (DOT) is con-
sidered to be non- inferior to standard self-administered
isoniazid for nine months in preventing progression to ac-
tive TB, and more likely to be completed than isoniazid
[12, 15]. Additionally, there is an alternative LTBI regimen
of 3 months of daily rifampin and isoniazid. This regimen
is used in parts of Europe and also carries the benefits of
short duration and low cost. [16] However, the regimen is
not currently on the list of CDC recommended regimens,
and is not commonly used in the US at this time, and so
was not included in this study.
There has been significant excitement about three
months of isoniazid and rifapentine as an expedited
treatment option, but many features of this treatment
make it less than ideal for certain patients and clinical
settings. While the isoniazid and rifapentine regimen of-
fers the promise of higher completion rates, likely due to
less cumbersome dosing and shorter duration, this ther-
apy is also significantly more expensive likely driven by
the recommended use of DOT [17–19], which may be
inconvenient for some patients, and requires a large re-
source commitment for the clinics that administer it.
Daily rifampin for four months has long been seen as
an alternative regimen [7] for people who cannot toler-
ate isoniazid for nine months, or who were exposed to
INH-resistant TB. Prior studies have demonstrated
higher completion rates with shorter rifampin-based reg-
imens compared to isoniazid [11, 20, 21]. Additionally,
in a recent review of LTBI treatment, rifampin was again
introduced as a potential regimen with increased com-
pletion rates compared to nine months of isoniazid,
though no direct comparisons were made between
rifampin and isoniazid-rifapentine [22]. With the intro-
duction of isoniazid plus rifapentine and rifampin only
regimens, isoniazid only therapy use appears to have de-
clined making a study of completion rates among these
regimens particularly useful.
Objective
To date, there have been no studies directly comparing
completion rates of isoniazid only, rifampin only, and
isoniazid and rifapentine regimens. Data on “actual use”
in the outpatient setting would be helpful to health care
providers to guide choice of therapy for individual pa-
tients. The aim of this study is to compare the rates of
completion of the three LTBI therapies across heteroge-
neous populations in various outpatient settings, includ-
ing primary care clinics, subspecialty clinics, and a
public health TB clinic.
Methods
We conducted a retrospective cohort study of all patients
who initiated treatment for LTBI with nine months of iso-
niazid, rifampin only, or isoniazid and rifapentine dis-
pensed at a hospital affiliated pharmacy or TB clinic
during 2009 or between July 1, 2013 and June 30, 2014.
Five hospital-affiliated clinics in Seattle, Washington par-
ticipated in this study: four outpatient clinics affiliated
with an urban academic tertiary care medical center, and
one county TB clinic. The outpatient clinics include a hos-
pital employee health clinic, a primary care clinic focused
on care of immigrants and refugees, a primary care clinic
focused on the care of homeless individuals, and a sub-
specialty infectious diseases clinic. Given that this was a
retrospective chart review and patient identifiers were
removed before entry into the secure database, subject
consent to participate was waived by the Institutional Re-
view Board (IRB) per standard practices at our institution.
The IRB at the University of Washington Human Subjects
Division approved this study (#43613).
Patients were identified for inclusion in the study if
they were 18 years old or older. For patients treated in
the hospital-affiliated outpatient clinics, pharmacy re-
cords were used to identify patients who were given a
prescription for isoniazid without ethambutol or rifam-
pin, rifampin alone, or isoniazid with rifapentine. For
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isoniazid monotherapy patients, records were queried
for those who initiated treatment in 2009, well before
the nation-wide isoniazid shortage and 9 months of iso-
niazid was standard of care. Records were queried again
for those who initiated treatment between July 1, 2013
and June 30, 2014 for all three regimens. Medical re-
cords for the TB clinic were held separately and LTBI
cases treated with the regimens of interest were identi-
fied in a TB Control Program database. Diagnosis of
LTBI was made by either tuberculin skin test (TST) or
interferon gamma release assay (IGRA) in combination
with chest x-ray. Screening for active and latent TB was
standard practice for patients in the international clinic,
homeless clinic and employee health due to the high risk
of exposure in those populations. The infectious diseases
clinic treated patients planning to undergo treatment of
another disease process with immunosuppressive therap-
ies. Patients from the Public Health Clinic, were
screened as contacts of active cases being treated by
Public Health. The sample size we had was determined
by the number of patients seen in our clinics during our
study period and so we did not calculate power. The
95% confidence intervals we present in Table 2 provide
the best range of plausible estimates. Only one person
was excluded from our chart review because it was de-
termined upon further chart review that the participant
had already completed therapy for LTBI prior to our
study time frame. Patients with HIV were not included
in this study, as this medical center has a separate HIV
clinic which sees HIV patients, and because of the po-
tential drug-drug interactions between antiretroviral
therapy and rifamycin-based regimens.
Patients were evaluated for LTBI treatment and
monitored for adverse effects during follow up visits.
When evaluating for side effects, specific side effects
such as liver function test (LFT) abnormalities, lab
abnormalities, and other known or common medica-
tion side effects were marked as present or absent,
whereas patient side effects were classified as “other”
if the patient reported a subjective side effect which
was not a known side effect of the medication regi-
mens (for example, a report of dizziness after taking
medications was classified as “other.”) Choice of treat-
ment regimen, frequency of follow-up visits, and fre-
quency of laboratory monitoring were selected by the
treating physician at his or her discretion based on
patients’ other comorbidities, medications, length of
therapy and cost. Patients on the nine-month isonia-
zid and four-month rifampin daily regimens were typ-
ically seen monthly in the public health clinics, and
monthly or less often in the outpatient clinics. Pa-
tients monitored less than monthly were monitored
this way because of poor attendance in clinic. When
present in clinic, regular monitoring was completed
as it would have been in a monthly monitoring scenario.
Patients on isoniazid and rifapentine were seen weekly for
DOT by either a nurse or an outreach worker. A small
number of the patients on isoniazid and rifapentine re-
ceived weekly phone calls or met virtually with an out-
reach worker via webcam, rather than in-person contact.
The public health TB clinic used a standard set of ques-
tions to check for specific side effects, whereas in all other
clinics, patients were asked a targeted review of systems at
the provider’s discretion to assess for side effects to the
regimens. Interpreters were used for non-English-
speaking patients.
The primary outcome was treatment completion. This
outcome was determined based on pharmacy records of
prescription fulfillment. Patients were considered to have
completed therapy if they filled prescriptions consecu-
tively to correspond to 270 doses of isoniazid within
12 months [7], 120 doses of rifampin in a 6 month
period [7] or 12 doses of isoniazid and rifapentine in a
4 month period [12].
We calculated counts, proportions, and means for
demographic, treatment, and health characteristics for
all participants combined and by treatment type. We
estimated counts and row proportions for treatment,
clinic, and monitoring type. We hypothesized these three
factors would be associated with completion of treat-
ment. We used Poisson regression models with a log
link and robust error variance to estimate unadjusted
and adjusted relative risks (RR) along with 95% confi-
dence intervals (CI) and p-values in lieu of logistic re-
gression since our outcome was common. We identified
potential confounders a priori based on their relation-
ship between the hypothesized factor and completion of
treatment. Confounders evaluated were specific to each
exposure of interest and included demographic (e.g. age,
type of insurance) and treatment characteristics (e.g.
clinic, treatment regimen, monitoring type) and were
modeled as categorized in Table 1. Potential confounders
that altered estimates, generally by more than 10%, were
retained in the adjusted models. Specifically, when deter-
mining the association between completion of therapy
and treatment regimen, we adjusted for frequency of
monitoring and when examining the association between
completion of therapy and type of monitoring, we ad-
justed for type of monitoring. Because type of monitor-
ing and treatment regimen may be related, we
conducted sensitivity analyses for these associations with
and without adjustment for type of monitoring and
treatment regimen, respectively. Additionally, we con-
ducted further sensitivity analyses post-hoc after noting
differences across treatment regimen in homelessness
and alcohol use. All analyses were conducted using Stata
13.1 [23]. The University of Washington Human Sub-
jects Division reviewed and approved this research.
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Results
A total of 393 participants were included in the study:
87 patients received three months of isoniazid and
rifapentine, 82 received four months of rifampin and 224
received nine months of isoniazid (Table 1). There were
more men represented in this study than women (55.5%
Table 1 Characteristics among all participants and stratified on treatment
All Participants (N = 393) Isoniazid + Rifapentine,
2013 only (N = 87)
Rifampin only, 2013
only (N = 82)
Isoniazid only, 2009
and 2013 (N = 224)a
p-value
n (%)b n (%)b n (%)b n (%)b
Genderc 0.93
Female 175 (44.5) 38 (43.7) 38 (46.3) 99 (44.2)
Age (years)c 43.6 (15.0) 43.2 (15.4) 43.4 (13.1) 43.8 (15.5) 0.94
Insuranced 0.19
Private 59 (18.0) 10 (15.2) 13 (22.0) 36 (17.8)
Government sponsored 76 (23.2) 16 (24.2) 17 (28.8) 43 (21.3)
Charity care 163 (49.9) 34 (51.5) 29 (49.2) 100 (49.5)
Other 29 (8.9) 6 (9.1) 0 (0.0) 23 (11.4)
Race/Ethnicityc <0.001
Caucasian 30 (7.9) 8 (9.9) 3 (3.7) 19 (8.8)
African or African American 94 (24.9) 18 (22.2) 20 (24.4) 56 (26.1)
Asian 161 (42.6) 19 (23.5) 40 (48.8) 102 (47.4)
Mexican or Other Hispanic 49 (13.0) 11 (13.6) 10 (12.2) 28 (13.0)
Pacific Islander 32 (8.5) 21 (25.9) 6 (7.3) 5 (2.3)
Other 12 (3.2) 4 (4.9) 3 (3.7) 5 (2.3)
Foreign Bornc 341 (90.7) 65 (79.3) 79 (98.8) 197 (92.1) <0.001
English Speakingc 203 (52.5) 60 (70.6) 38 (46.3) 105 (47.7) 0.001
Homeless/marginally housee 45 (12.3) 24 (31.2) 2 (2.5) 19 (9.1) <0.001
Number of other medical problemsc 0.01
0 178 (45.3) 38 (43.7) 51 (62.2) 89 (39.7)
1-2 119 (30.3) 29 (33.3) 19 (23.2) 71 (31.7)
3+ 96 (24.4) 20 (23.0) 12 (14.6) 64 (28.6)
Number of medicationsc <0.001
0-1 139 (35.4) 0 (0.0) 56 (68.3) 83 (37.1)
2-3 138 (35.1) 57 (65.5) 12 (14.6) 69 (30.8)
3+ 116 (29.5) 30 (34.5) 14 (17.1) 72 (32.1)
Any tobacco use at start of therapyc 49 (12.5) 19 (21.8) 11 (13.4) 19 (8.5) 0.01
Any alcohol at start of therapyc 52 (13.2) 21 (24.1) 10 (12.2) 21 (9.4) 0.002
Clinicc <0.001
Infectious Diseases 17 (4.3) 8 (9.2) 0 (0.0) 9 (4.0)
Public Health 263 (66.9) 69 (79.3) 67 (81.7) 127 (56.7)
International Clinic 68 (17.3) 0 (0.0) 15 (18.3) 53 (23.7)
Homeless Clinic 18 (4.6) 5 (5.8) 0 (0.0) 9 (4.0)
Employee Health 27 (6.9) 5 (5.8) 0 (0.0) 22 (9.8)
Type of Monitoringc <0.001
Weekly DOT/Phone calls 87 (22.2) 84 (96.6) 1 (1.2) 2 (0.9)
Monthly visit 139 (35.5) 2 (2.3) 66 (80.5) 71 (31.8)
Less often 166 (42.4) 1 (1.2) 15 (18.3) 150 (67.3)
a 205/224 were treated in 2009 and 19/224 were treated in 2013. In 2009, 7/9 patients were treated in the Infectious Diseases Clinic, 123/127 at the Public Health
clinic, 48/53 in International Clinic, 10/13 in the Homeless Clinic, and 17/22 in Employee Health
b All estimates are percents except for age which is a mean (standard deviation)
c Less than 5% of data missing; d 16.8% of data are missing; e 7.1% of data are missing
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compared to 44.5%). The average age of study partici-
pants was 43.6 years. Foreign-born and non-English
speaking participants were less likely to receive isoniazid
and rifapentine. Treatment regimens differed by clinic
and type of monitoring.
Patients treated with four months of rifampin were as
likely to complete therapy as those on three months of
isoniazid and rifapentine. Patients on nine months of
isoniazid were less likely to complete treatment than pa-
tients on four months of rifampin or three months of
isoniazid and rifapentine with adjusted relative risk of
0.66 (95% CI 0.56, 0.79) and 0.59 (95% CI 0.36, 0.93), re-
spectively (Table 2). These associations remained statisti-
cally significant and in the direction anticipated after
adjusting for clinic location and type of monitoring. In
our sensitivity analyses, this association between treat-
ment regimen and completion was similar with and
without adjustment for type of monitoring.
Patients treated in the employee or refugee clinics
were less likely than patients in the public health TB
clinic to complete therapy with adjusted RR of 0.37 (95%
CI 0.20, 0.69) and 0.64 (95% CI 0.47, 0.85) respectively
(all p-values ≤0.01). Patients treated in the homeless
clinic or infectious diseases clinic appeared to be less
likely to complete treatment than patients in the public
health TB clinic, although the differences were not sta-
tistically significant with adjusted RR of 0.65 (95% CI
0.38, 1.09) and RR of 0.74 (95% CI 0.48, 1.12), respect-
ively (Table 2).
In unadjusted analyses, patients with monthly or less
frequent monitoring were less likely to complete therapy
than those with weekly DOT with RR of 0.86 (95% CI
0.75, 0.98) and RR of 0.60 (95% CI 0.51, 0.72). However,
these associations were no longer apparent after adjust-
ing for clinic location and treatment type with RR of
1.12 (95% CI 0.721, 1.76) and RR of 1.21 (95% CI 0.48,
1.12), respectively (Table 2). In sensitivity analyses that
examined this association between frequency of moni-
toring and treatment completion without adjusting for
treatment regimen, there is a significant association with
RR of monthly monitoring of 0.82 (95% CI 0.72, 0.94)
and less frequent monitoring of 0.73 (95% CI 0.61, 0.89)
compared to weekly DOT. This difference in association
with and without adjustment for treatment regimen is
likely related to the strong association between treat-
ment regimen and monitoring type.
Table 2 Factors associated with completion of therapy
Not Completed Completed Unadjusted Adjusted
n percent n percent RR 95% CI p-value RR 95% CI p-value
Type of Therapya,b
Isoniziad + Rifpaentine 13 14.9 74 85.1 Reference Reference
Rifampin only 12 14.6 70 85.4 1.00 0.88, 1.14 0.96 0.88 0.55, 1.38 0.57
Isoniazid only 107 48.2 115 51.8 0.61 0.52, 0.71 <0.001 0.58 0.36, 0.93 0.02
Isoniazid only (vs rifampin only) 0.61 0.52, 0.71 <0.001 0.66 0.56, 0.79 <0.001
Clinicb,c
Public Health 59 22.5 203 77.5 Reference Reference
Employee Health 20 74.1 7 25.9 0.33 0.18, 0.64 <0.001 0.37 0.20, 0.69 <0.01
International 37 54.4 31 45.6 0.59 0.45, 0.77 <0.001 0.64 0.47, 0.85 <0.01
Homeless 9 52.9 8 47.1 0.61 0.37, 1.01 0.06 0.65 0.38, 1.09 0.10
Infectious Diseases 7 41.2 10 58.8 0.76 0.51, 1.14 0.18 0.74 0.48, 1.12 0.16
Type of monitoringa,c
Weekly DOT/phone calls 13 15.1 73 84.9 Reference Reference
Monthly clinic visits 38 27.3 101 72.7 0.86 0.75, 0.98 0.03 1.12 0.71, 1.76 0.62
Less often 81 48.8 85 51.2 0.60 0.51, 0.72 <0.001 1.21 0.75, 1.96 0.43
Side effectsc 37 28.2 94 71.8 1.13 0.98, 1.30 0.09 1.03 0.90, 1.18 0.66
Number of other medical problemsa,d
0 47 26.6 130 73.5 Reference Reference
1-2 42 35.3 77 64.7 0.88 0.75, 1.03 0.12 1.00 0.84, 1.19 1.00
3+ 43 45.3 52 54.7 0.75 0.61, 0.91 0.01 1.08 0.88, 1.33 0.47
Abbreviations: RR Relative Risk, 95% CI 95% Confidence Interval
a Adjusted for clinic type
b Adjusted for type of monitoring
c Adjusted for treatment
d Adjusted for insurance
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We evaluated race/ethnicity, foreign born status and
English-speaking for all adjusted associations presented
in Table 2. None of these variables altered our associa-
tions or inference (p-values, confidence intervals) in any
material way (e.g. there was <10% change in our esti-
mates and no change in our p-values being above or
below 0.05). We did not adjust for these factors in our
analysis since they did not confound our associations.
Additionally, we compared our reported results for all
adjusted associations in Table 2 with models that also ad-
justed for homelessness and alcohol use. We observed no
material difference in the associations (all were in the
same direction and statistical significance did not change).
There was no difference in reporting of any side effects
in those who completed versus those who did not
complete therapy with RR of 1.03 (95% CI 0.90, 1.18)
(Table 2). We hypothesized a priori that those patients
with three or more medical problems would complete
therapy less often. However, after adjusting for the clinic
type and insurance, there was no significant difference
in completion rates between patients with more medical
problems compared to patients with fewer medical prob-
lems with RR of 1.08 (95% CI 0.88, 1.33) (Table 2).
Key Findings
This retrospective cohort study demonstrated compar-
able completion rates between the novel three months
of isoniazid and rifapentine and the less often used four
months of rifampin. Both regimens had superior rates of
completion compared to nine months of isoniazid. Cur-
rently, four months of rifampin is considered a second-
ary alternative, rather than a comparable choice with
nine months of isoniazid or 12 weeks of rifapentine with
isoniazid, which are the current standard. Given the
lower cost to patients and health care settings of four
months of rifampin compared to three months of isonia-
zid and rifapentine, we suggest that providers consider
four months of rifampin as an alternative first-line op-
tion for LTBI treatment among the appropriate popula-
tions. Use of rifampin would offer significant cost
savings to patients and health care systems in the United
States and abroad. Additionally, improved rates of treat-
ment completion would help reduce incidence of active
cases in the United States and around the world.
Discussion
With the publication in 2011 of non-inferiority of three
months of isoniazid and rifapentine [15] to nine months
of isoniazid, many have brought this treatment into the
armamentarium against LTBI. Subsequent statistical
modeling exercises suggest that three months of isonia-
zid and rifapentine is more effective and saves money
compared to nine months of isoniazid because of higher
rates of treatment completion and subsequent
prevention of activation of TB [19, 24]. With this retro-
spective cohort study, we confirmed prior findings that
three months of isoniazid and rifapentine is associated
with higher completion rates relative to nine months of
isoniazid. Additionally, these findings were true across a
variety of patient populations and outpatient practice
settings, reinforcing that three months of isoniazid and
rifapentine is an excellent treatment option for patients
who are not likely to adhere to nine months of isoniazid.
New and exciting treatments may not always be the
best choice [25]. Rifamycin-based regimens are known
to have low toxicity [8], however, all rifamycin based reg-
imens share similar side effect profiles, including discol-
oration of bodily fluids (a use-limiting effect for some
patients), and interactions with many common medica-
tions, including anticoagulants, HIV medications, and
contraception.
The results of this study have important practical im-
plications for providers, patients, and health care sys-
tems. The two regimens likely have similar side effect
profiles [15, 26], but four months of rifampin does not
require DOT and is less expensive than three months of
isoniazid and rifapentine. Both four months of rifampin
[8] and three months of isoniazid plus rifapentine [15]
are also highly effective against latent TB, with similar
efficacy compared to placebo or isoniazid monotherapy,
respectively. While rifampin-only regimens are currently
considered an alternative regimen, our findings suggest
that rifampin-only regimens should be considered not
just as an alternative to nine months of isoniazid, but as
a comparable first-line regimen to three months of iso-
niazid and rifapentine and perhaps even superior to nine
months of isoniazid given much better completion rates.
Our data show that the type of treatment offered was
a strong predictor of treatment completion whereas
monitoring type was not. This is contrary to our a priori
hypothesis in which we anticipated DOT regimens
would be superior due to the nature of DOT. No sig-
nificant difference was found in completion rates be-
tween DOT and the rifampin-based self-administered
regimen. In other words, non-adherence to the rec-
ommended follow-up was not associated with treat-
ment non-completion. Our data represent real-life
scenarios that are often missing from research set-
tings, which can make research findings challenging
to apply to the imperfect clinical setting. These find-
ings suggest that self-administered four months of ri-
fampin may be able achieve high compliance rates
similar to the rates of three months of isoniazid and
rifapentine, without the costs of DOT to both pa-
tients and health care systems. These findings under-
score the utility of four months of rifampin for
providers who do not have the resources available for
DOT in the outpatient setting.
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We also found significantly higher completion rates at
the public health TB clinic compared to primary care
clinics. The comparative success of the TB clinic may be
the result of having staff that have been trained to focus
on engagement of patients in LTBI treatment, whereas
primary care visits often attempt to address multiple is-
sues in a 15-min visit without dedicated staff to address
LTBI treatment. Alternatively, the relative success of the
public health TB clinic may be due in part to patient
motivation to complete therapy because personal experi-
ence through close contact to active TB cases.
While a homeless incentive program was used in this
study, we did not see a higher rate of completion in the
homeless clinic compared to other sites. This is in line
with recent findings that incentive programs may have
short term effects on clinic attendance, but do not seem
to reliably increase the number of people completing
treatment for LTBI [27].
Our study has limitations. First, given that our study
was retrospective and not randomized, the design limits
the strength of the conclusions regarding the true
equivalence of the regimens. Provider discretion should
still guide the choices between rifampin only regimens
versus INH-rifapentine, which may still be of greater
utility in patient populations with historically low adher-
ence, such as homeless patients and those actively using
alcohol or other substances. Second, all participating
clinics are located in one US city. Though we include a
representative mix of foreign-born and homeless persons
(see Table 1), our findings may not be generalizable to
all populations in all settings. Further research is needed
to clarify completion rates in other actual use settings
such as other clinic settings, different cities, rural areas,
and other states and countries. Third, there were more
patients from the TB clinic than the other clinic sites,
which may have limited our ability to detect differences
in the smaller samples of the non TB clinic patients.
Fourth, each clinic has unique patient populations and
characteristics that limit the interpretation of compari-
sons among different clinics. These regimens have differ-
ent roles in how they are employed in LTBI treatment
programs depending on provider and patient preferences
and needs. Fifth, treatment regimens also varied over
time based on standard of care. Rifampin alone was used
much less frequently in our medical center in 2009, as
INH was the standard of care. Similarly, once our med-
ical center made the switch to isonaizid plus rifapentine
and rifampin only regimens, the number of people being
treated with INH alone was quite small, and a simultan-
eous comparison of the three regimens using only 2013
data would have been underpowered to detect a differ-
ence. To adequately compare the three regimens, we
pooled data from two different time points in order to
have large enough sample sizes to detect a true
difference. We did not set up our analysis to compare
INH in 2009 to INH in 2013 because that was not the
primary outcome of interest. Rather, the goal was to
compare completion rates for INH, rifampin and INH
plus rifapentine regimens in an “actual use” scenario (ra-
ther than research settings, where monitoring and com-
pliance tend to be more rigorous than a “true” patient
might actually adhere to). Sixth, our study was limited to
adults and excluded individuals with HIV co-infection.
Lastly, since our sample size was determined by the
number of patients in our clinics we may have had insuf-
ficient power to detect associations. Population-based
studies and randomized clinical trials are needed to clar-
ify factors associated with non-completion of these regi-
mens, and to assess side effects and adverse events.
Conclusions
In conclusion, this outpatient-based comparison of four
months of rifampin, three months of isoniazid and rifa-
pentine, and nine months of isoniazid demonstrates
comparable completion rates between four months of ri-
fampin and three months of isoniazid and rifapentine
while taking into consideration the monitoring fre-
quency. Given the similar side effect profile but signifi-
cant cost savings with four months of rifampin, we
suggest that four months of rifampin be considered ex-
changeable with three months of isoniazid and rifapen-
tine and nine months of isoniazid for treatment of latent
tuberculosis infection.
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